Objectives: Infl ammatory bowel diseases (IBD) are caused by the failure of immunoregulatory mechanisms due to external environmental factors in genetically predisposed individuals. Probiotics and prebiotics could be used in prevention and therapy of many disorders of gastrointestinal tract including ulcerative colitis. Probiotics are living microorganisms with good tolerability and minimal risk, which confer a health benefi t for the host when administered in adequate amounts. Their effect is closely related to maintaining the natural function of the intestinal fl ora. In this respect, they are indispensable prebiotics to protect or reduce the incidence of infl ammatory lesions in diseases of the digestive tract. Conclusion: Ingestion of probiotics and prebiotics may provide some clues in developing a new class of therapeutic agents for the treatment/prevention of IBD and colitis-associated cancer (CAC) in the future (Tab. 2, Ref. 26). Full Text in PDF www.elis.sk.
Chronic nonspecifi c infl ammatory bowel diseases (Infl ammatory bowel diseases, IBD) are serious medical and socio-economic problems with continuing increase in the incidence and prevalence. The most important nosological units in this group of diseases are Crohn's disease (Morbus Crohn -MC) and ulcerative colitis (Colitis ulcerosa -CU). A high morbidity, signifi cant early and late complications, and decreased quality of life is the reason for seeking new possibilities for the prevention, rational diagnosis and treatment.
Ulcerative colitis -defi nition, incidence
Ulcerative colitis (Colitis ulcerosa -CU) is a chronic, nonspecifi c infl ammatory bowel disease characterized by exudative, hemorrhagic -catarrhal and ulcerative changes mainly of rectal mucosa and submucosa with a possible extension on the remaining part of the intestine.
The incidence of CU is associated with two age peaks. First observed is in the younger middle generation, with a maximum between 20 and 40 years of life. The other is the end of the fi fth and the beginning of the sixth decade of life. About 15 % of patients with CU are aged over 60 years. The highest incidence and prevalence of CU is in Israel, Britain and North America. CU incidence in Europe is about 10.0/100 000 in North America from 2.2 to 14.3/100 000 inhabitants. The prevalence of CU in Europe is 2-243/100 000 inhabitants (the largest is in northern England). In North America, the prevalence is 170/100 000 and in the Czech Republic, it is 10.4-42/100 000. In Slovakia, the expected incidence is 16.8 CU/100 000 inhabitants (Gregus, 2006) . Ulcerative colitis is not rare even in childhood. At the end of the 2003, there were 134 children diagnosed with CU (62 boys, 72 girls) aged 0-18 years with the average age of manifested CU 11.68±0.36 years. CU incidence in children in Slovakia in this period was 1.63 to 2.12/100 000 inhabitants (Čierna et al, 2008) .
The National Cancer Registry of Slovak Republic process long-term data on cancer incidence in the Slovak Republic, statistically analyzes and evaluates the incidence of malignant tumours in the country, creates designs and implements epidemiological studies that indicate not only the current scope, development and distribution of diseases and deaths from malignant tumours, but also suggests their development and possible causes and associ- Men usually die on cancer of the trachea, bronchus and lung (C33, C34), followed by colorectal malignancies (C18 -C21), colon (C18) and prostate (C61). For women, the highest mortality rate (number of deaths per 100 000 women) was malignant tumours of breast (C50), colon (C18), colorectal (C18 -C21) and cancer trachea, bronchus and lung (C33, C34).
The aetiology of ulcerative colitis is not yet understood. Anticipated are synergies of the three main groups of factors:
-Genetic (familial incidence of 15-20 %, 35-50 % monozygote twins),
-Environmental (environmental impacts, bacterial antigens, stress, smoking, hygiene, nutrition),
-Immunology (immune response, mucosal immune system defect).
The interaction of genetic, environmental and immunology factors suggests the current concept of the pathophysiology of infl ammatory diseases. In genetically susceptible individuals, abnormal communication between the intestinal microbial fl ora and mucosal immune system form the basis of the defect, which is accompanied by mucosal infl ammatory lesions of the gastrointestinal tract. The course of CU is characterized by an impact frequency of unpredictable occurrence of relapse (acute infl ammation) and remission (infl ammation in decline).
Infl ammatory bowel disease (IBD) is a group of chronic infl ammatory disorders that affect individuals throughout life. Although the aetiology and pathogenesis of IBD are largely unknown, studies with animal models of colitis indicated that dysregulation of host/microbial interactions included that the loss of epithelial and cell barrier function were pre-requisite for the development of IBD. Patients with long-standing IBD have a higher risk of developing colitis-associated cancer (CAC) approximately 8-10 years after the initial diagnosis as compared to general populations. In addition to genomic instability (genomic instability -chromosomal and microsatellite instability, which is important for the development of colon cancer, however, the process that causes this genomic instability is not completely understood) that underlies the process of tumorigenesis, continuous infl ammation in the intestine seems to be a key factor in CAC development since chronic infl ammation is associated with an overexpression of proinfl ammatory cytokines, chemokines, growth factors as well as their receptors, and reactive oxygen species. In particular, oxidative injury, causing widespread DNA damage, leads to the inception of cancer (Kanneganti et al, 2011 ).
Therapy of CU

1) Standard (medical) therapy
Standard therapy of CU used drugs -Aminosalicylates (5-aminosalicylic acid, 5-ASA, mesalazine), together with glucocorticoids are the essential medication. Aminosalicylates are still considered the fi rst-line treatment for mild to moderately severe CU, shown effective in maintaining remission of the disease. 5-ASA preparations are administered in the form of pro-drug (balsalazid, olsalazine), the active ingredient 5-ASA is released from them mainly in the colon. Glucocorticoids -about 34-45 % of patients with CU requires treatment with glucocorticoids. Immunomodulatory treatment is indicated in case of the lack of effect of treatment with glucocorticoids.
2) Surgical therapy 3) Alternative or adjuvant therapy --another form of therapy
A high importance in the long term is the supportive therapy, which focuses on improving the overall health of the patient. For Crohn's disease and ulcerative colitis, there is no single diet, as we know in diabetic and coeliac disease. In essence, the principle of avoiding foods that cause nausea or abdominal pain, which may vary for each patient. The exact mechanism of action of probiotics and prebiotics is unknown, it is assumed that they act through microbiological modifi cations, inhibiting intestinal pathogens and stabilizing the immunological barriers in the gastrointestinal mucosa, reducing the production of proinfl ammatory cytokines. The research suggested that probiotics may offer an alternative or adjuvant approach to conventional therapy by altering the intestinal microfl ora and modulating the host immune system (Fedorak and Madsen, 2004; Rolle, 2000) .
1) The organism must be fully identifi ed: genus, species and strain 2) It must be safe for consumption:
-Not pathogenic or carrying antibiotic resistance genes -Not degrading to intestinal mucosa or conjugating for bile acids 3) It must survival intestinal transit: Acid and bile tolerant 4) It must adhere to mucosal surface and colonize the intestine (at least briefl y) 5) It must possess documented health effects:
-Produce antimicrobial substances and antagonize pathogenic bacteria -At least one phase 2 study documenting benefi t 6) It must be stable during processing and storage
Tab. 1. Criteria for use as a probiotic.
Author
Number Treatment Duration study 
Probiotics, prebiotics
Probiotics are defi ned as living food supplements or components of bacteria that have been shown benefi cial effects on human health (Salminen et al, 1998) . A probiotic bacterium is required to fulfi l certain criteria (Tab. 1), (Borchers et The protective effect of probiotics on colon tumours includes suppression of increase in metabolic activity of bacteria forming carcinogenic, mutagenic substances, binding of carcinogens, formation of butyrate and other substances stimulating apoptosis in abnormal cells, immunostimulatory effects -stimulation of humoral and cellular immunity, protective effects of idiopathic intestinal infl ammations and inhibition of the conversion of bile acids into secondary and tertiary. Clinical studies investigated the effect of the probiotics in patients with ulcerative colitis in the induction of remission (treatment of acute ulcerative colitis) and in the maintaining of remission or the preventing of relapse. An overview of 10 studies covering totally 861 patients with CU is summarized in the Table 2 . The number of patients in the studies varied from 18 to 327 patients. The duration of study was different from 4 weeks to 1 month (1 study), 6 weeks (1 study), 8 weeks (2 studies), 12 weeks (1 study), and more then 12 months (5 studies). In one study (116 and 327 patients), the probiotic non-pathogenic E. coli strain Nissle 1917 was administered. This probiotic intervention was equivalent to mesalazine, drug that is considered the gold standard in maintaining remission in patients with CU and the best evidence supporting the use of probiotics in the treatment of CU. The second largest study (187 patients) used Lactobacillus rhamnosus GG compared with mesalazine and differences were not observed in the relapse rate at 6 and 12 months, but patients with LGG did not relapse for a long time and it was suitable for the maintenance of remission. In the small study (30 patients), patients received BIFICO capsules (Enterococci, Bifi dobacteria, Lactobacilli) to maintain remission induced by sulfasalazine. Patients receiving BIFICO demonstrated lower levels of proinfl ammatory cytokines and nuclear factor kappa B (NF-ĸB) and increased levels of IL-10 compared to patients receiving placebo. At the same study, the relapse in patients with BIFICO was signifi cantly less frequent. Other small (18 patients), double-blind, randomized study used synbiotics compound with prebiotic (Synergy 1) and probiotics (B. longum) to treat patients with active CU. One month later the patients demonstrated an improvement in clinical parameters.
Prebiotics such as lactulose, inulin, psyllium and other oligosaccharides (found in onions, garlic, asparagus, leeks, artichoke, bananas, tomatoes, wheat, oats, soy beans, and other plants) are defi ned as non-digestible selectively fermented ingredients (food ingredients) that allow specifi c changes in the composition and/ or activity of microorganisms in the GIT, which have a positive impact on the health of the host (Gibson et al, 2004 ). Synbiotics are a combination of a prebiotic and a probiotic, such as inulin and Lactobacillus rhamnosus GG or Bifi dobacter longum. The positive effect of prebiotics was shown by authors (Guarner, 2007; Hedin et al, 2007; Leenen and Dieleman, 2007; Looijer et al, 2009) , and suggested the possibility of the effective use of prebiotics, which were relatively safe, inexpensive, did not require administration of large quantities and were readily available.
In the study on the possibilities of the prevention and treatment of colitis in addition to clinical trials, animal experimental models are important, which could clarify the differences in the responses to probiotic therapy in animals in comparison with humans (Grimoud et al, 2010; Xia et al, 2011). The implementation of new evidence may help to change of sight in probiotics and prebiotics, which they would receive from the edge of the pharmaceutical interest in the mainstream clinical practice.
Conclusion
We can say that probiotics have generally benefi cial effects on gastrointestinal diseases. It is believed that probiotics may act through competitive inhibition of intestinal colonization by pathogens producing endotoxin, improving gut barrier function and reducing production of proinfl ammatory cytokines. At present, there is no clear answer, which probiotic is the best, because the effect of probiotics is specifi c for the strain. The trend, however, tends to increase the effectiveness of probiotics, as well as the mutual application of probiotics with the substrates necessary for their growth -prebiotics or other substances of natural origin. Mutual combination of probiotics and prebiotics can maximize their benefi cial effects on the organism and reaching the broader synergistic effect, but the provided hypothesis requires further research. Additional scientifi c efforts should be directed to clarify the mechanism of action and explaining ineffi ciency in some indications. The outstanding issues in the future are the choice of probiotic strain, respectively combinations of strains, combinations of probiotics and prebiotics, the dose and duration of administration.
